Tumor News and Research

RSS

VA develops FATE survey to access treatment quality at the end of patients' lives

Though there have been significant improvements in the treatment of head and neck cancer, there is still a lack of data on the experience of end of life care for head and neck cancer patients, according to a new study published in the May 2011 issue of Otolaryngology-Head and Neck Surgery.

2 May 2011

Pediatric urology research papers published in two Elsevier journals

The first World Congress of Pediatric Urology was held in San Francisco in May 2010, bringing together the largest and most successful international congregation of pediatric urologists ever assembled. As part of a collaborative effort, The Journal of Urology and the Journal of Pediatric Urology have together published the landmark papers presented at this meeting.

2 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Three hundred neurosurgeons to participate in Central Park softball tournament

With summer just around the corner, that means the Annual Neurosurgery Charity Softball Tournament will take place in Central Park for the eighth consecutive year.

30 Apr 2011

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Combining computerized tomography with fluorodeoxyglucose positron emission tomography images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta.

30 Apr 2011

Mammography screening can benefit women under age 50

Screening mammography benefits women between 40 and 49 years of age, and excluding this population from annual exams under the revised Preventative Service Task Force mammography guidelines would negatively impact survival, according to research presented this week at the American Society of Breast Surgeons Annual Meeting.

30 Apr 2011

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

Reimbursement policy influences choice of IMRT for treating breast cancer

What Medicare would pay for and where a radiation oncologist practiced were two factors that strongly influenced the choice of intensity-modulated radiation therapy (IMRT) for treating breast cancer, according to an article published April 29 online in the Journal of the National Cancer Institute. The use of IMRT and the cost of radiation therapy increased sharply over the period of the study.

29 Apr 2011

Proton radiography imaging helps lower radiation dosage to pediatric cancer patients

Proton radiography imaging used prior to and during proton treatments for pediatric cancer patients provides for more accurate treatment delivery and a lower dose of radiation compared to standard diagnostic X-rays and cone beam CT, according to a study presented today at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Researchers discover possible role of SCCA in breast cancer progression

In an analysis of more than 1,300 human breast tissue samples, a team of Stony Brook University School of Medicine researchers discovered a possible role of the squamous cell carcinoma antigen in the progression of breast cancer.

29 Apr 2011

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Experts from stem cell programs at respected research centers around the country will present information at an April 30 conference on stem cell therapy for neurological disorders, hosted by the Department of Neurosurgery at Cedars-Sinai Medical Center in collaboration with the Genetics Policy Institute of Wellington, Fla.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO Pharmaceuticals, Inc. today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011.

28 Apr 2011

New control point for suppressing cancer cell growth

Dana-Farber Cancer Institute scientists have discovered new details of how cancer cells escape from tumor suppression mechanisms that normally prevent these damaged cells from multiplying. They also demonstrated a potential link between this cell proliferation control mechanism and the cognitive deficits caused by Down syndrome.

28 Apr 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

New discoveries on polycystin-1 can lead to novel kidney disease treatment

Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

27 Apr 2011